{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:11:53Z","timestamp":1794085913278,"version":"4.8.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Alcohol use disorder (AUD) and anxiety disorders (AnxD) are prevalent health concerns in clinical practice which frequently co-occur (AUD-AnxD) and compound one another. Concurrent AUD-AnxD poses a challenge for clinical management as approaches to treatment of one disorder may be ineffective or potentially counterproductive for the other disorder.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case Presentation<\/jats:title>\n                <jats:p>We present the case of a middle-aged man with anxiety disorder, AUD, chronic pain, and gamma-hydroxybutyrate use in context of tapering prescribed benzodiazepines who experienced severe alcohol withdrawal episodes during a complicated course of repeated inpatient withdrawal management. After medical stabilization, the patient found significant improvement in symptoms and no return to alcohol use with a regimen of naltrexone targeting his AUD, gabapentin targeting both his AUD and AnxD, and engagement with integrated psychotherapy, Alcoholics Anonymous, and addictions medicine follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Proper recognition and interventions for AUD and AnxD, ideally with overlapping efficacy, can benefit individuals with comorbid AUD-AnxD. Gabapentin, tobacco cessation, and integrated psychotherapy have preliminary evidence of synergistic effects in AUD-AnxD. Meta-analysis evidence does not support serotoninergic medications (e.g. selective serotonin reuptake inhibitors) which are commonly prescribed in AnxD and mood disorders as their use has not been associated with improved outcomes for AUD-AnxD. Additionally, several double-blind placebo-controlled randomized trials have suggested that serotonergic medications may worsen alcohol-related outcomes in some individuals with AUD. Areas for future investigation are highlighted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-022-00344-z","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T17:16:59Z","timestamp":1667927819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Alcohol use disorder with comorbid anxiety disorder: a case report and focused literature review"],"prefix":"10.1186","volume":"17","author":[{"given":"Victor","family":"Mocanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9412-6699","authenticated-orcid":false,"given":"Evan","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"issue":"8","key":"344_CR1","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","volume":"72","author":"BF Grant","year":"2015","unstructured":"Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry Aug. 2015;72(8):757\u201366. doi:https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0584.","journal-title":"JAMA Psychiatry Aug"},{"issue":"Suppl 1","key":"344_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-244X-14-S1-S1","volume":"14","author":"MA Katzman","year":"2014","unstructured":"Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):1. doi:https:\/\/doi.org\/10.1186\/1471-244X-14-S1-S1.","journal-title":"BMC Psychiatry"},{"key":"344_CR3","doi-asserted-by":"publisher","unstructured":"Anker JJ, Kushner MG. Co-Occurring Alcohol Use Disorder and Anxiety: Bridging Psychiatric, Psychological, and Neurobiological Perspectives. Alcohol Res. 2019;40(1)doi:https:\/\/doi.org\/10.35946\/arcr.v40.1.03.","DOI":"10.35946\/arcr.v40.1.03"},{"issue":"3","key":"344_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/alcalc\/36.3.249","volume":"36","author":"M Driessen","year":"2001","unstructured":"Driessen M, Meier S, Hill A, Wetterling T, Lange W, Junghanns K. The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. Alcohol Alcohol. 2001 May-Jun. 2001;36(3):249\u201355. doi:https:\/\/doi.org\/10.1093\/alcalc\/36.3.249.","journal-title":"2001 May-Jun"},{"key":"344_CR5","unstructured":"British Columbia Centre on Substance Use (BCCSU), B.C. Ministry of Health, B.C. Ministry of Mental Health and Addictions. Provincial Guideline for the Clinical Management of High-Risk Drinking and Alcohol Use Disorder. BCCSU; 2019. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2021\/01\/AUD-Guideline.pdf."},{"issue":"5","key":"344_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4088\/PCC.08l00714","volume":"11","author":"M Hertzman","year":"2009","unstructured":"Hertzman M, Patt IS, Spielman LA. Open-label trial of acamprosate as a treatment for anxiety. Prim Care Companion J Clin Psychiatry. 2009;11(5):267. doi:https:\/\/doi.org\/10.4088\/PCC.08l00714.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"9","key":"344_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/add.14655","volume":"09","author":"HR Kranzler","year":"2019","unstructured":"Kranzler HR, Feinn R, Morris P, Hartwell EE. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction. 2019;09(9):1547\u201355. doi:https:\/\/doi.org\/10.1111\/add.14655. 114 ) .","journal-title":"Addiction"},{"key":"344_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0249","author":"RF Anton","year":"2020","unstructured":"Anton RF, Latham P, Voronin K, et al. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial. JAMA Intern Med. Mar 2020. doi:https:\/\/doi.org\/10.1001\/jamainternmed.2020.0249.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"344_CR9","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1177\/0269881109102623","volume":"24","author":"G Martinotti","year":"2010","unstructured":"Martinotti G, Di Nicola M, Tedeschi D, et al. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol Sep. 2010;24(9):1367\u201374. doi:https:\/\/doi.org\/10.1177\/0269881109102623.","journal-title":"J Psychopharmacol Sep"},{"issue":"7","key":"344_CR10","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/add.13324","volume":"111","author":"RV Smith","year":"2016","unstructured":"Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addict 07. 2016;111(7):1160\u201374. doi:https:\/\/doi.org\/10.1111\/add.13324.","journal-title":"Addict 07"},{"key":"344_CR11","doi-asserted-by":"publisher","first-page":"CD012557","DOI":"10.1002\/14651858.CD012557.pub2","volume":"11","author":"S Minozzi","year":"2018","unstructured":"Minozzi S, Saulle R, R\u00f6sner S. Baclofen for alcohol use disorder. Cochrane Database Syst Rev Nov. 2018;11:CD012557. doi:https:\/\/doi.org\/10.1002\/14651858.CD012557.pub2.","journal-title":"Cochrane Database Syst Rev Nov"},{"key":"344_CR12","doi-asserted-by":"publisher","first-page":"CD007505","DOI":"10.1002\/14651858.CD007505.pub2","volume":"1","author":"JC Ipser","year":"2015","unstructured":"Ipser JC, Wilson D, Akindipe TO, Sager C, Stein DJ. Pharmacotherapy for anxiety and comorbid alcohol use disorders. Cochrane Database Syst Rev Jan. 2015;1:CD007505. doi:https:\/\/doi.org\/10.1002\/14651858.CD007505.pub2.","journal-title":"Cochrane Database Syst Rev Jan"},{"issue":"1","key":"344_CR13","first-page":"38","volume":"24","author":"S Beaulieu","year":"2012","unstructured":"Beaulieu S, Saury S, Sareen J, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. Ann Clin Psychiatry Feb. 2012;24(1):38\u201355.","journal-title":"Ann Clin Psychiatry Feb"},{"key":"344_CR14","doi-asserted-by":"publisher","first-page":"CD008581","DOI":"10.1002\/14651858.CD008581.pub2","volume":"04","author":"R Agabio","year":"2018","unstructured":"Agabio R, Trogu E, Pani PP. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. Cochrane Database Syst Rev. 2018;04:4:CD008581. doi:https:\/\/doi.org\/10.1002\/14651858.CD008581.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"344_CR15","doi-asserted-by":"publisher","first-page":"e1003822","DOI":"10.1371\/journal.pmed.1003822","volume":"10","author":"S Grant","year":"2021","unstructured":"Grant S, Azhar G, Han E, et al. Clinical interventions for adults with comorbid alcohol use and depressive disorders: A systematic review and network meta-analysis. PLoS Med. 2021;10(10):e1003822. doi:https:\/\/doi.org\/10.1371\/journal.pmed.1003822. 18 ) .","journal-title":"PLoS Med"},{"issue":"9","key":"344_CR16","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/acer.12802","volume":"39","author":"DA Charney","year":"2015","unstructured":"Charney DA, Heath LM, Zikos E, Palacios-Boix J, Gill KJ. Poorer Drinking Outcomes with Citalopram Treatment for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial. Alcohol Clin Exp Res Sep. 2015;39(9):1756\u201365. doi:https:\/\/doi.org\/10.1111\/acer.12802.","journal-title":"Alcohol Clin Exp Res Sep"},{"issue":"1","key":"344_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1530-0277.2007.00555.x","volume":"32","author":"JH Krystal","year":"2008","unstructured":"Krystal JH, Gueorguieva R, Cramer J, Collins J, Rosenheck R, Team VCNS. Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, \u201cNaltrexone in the treatment of alcoholism\u201d. Alcohol Clin Exp Res Jan. 2008;32(1):85\u201391. doi:https:\/\/doi.org\/10.1111\/j.1530-0277.2007.00555.x.","journal-title":"Alcohol Clin Exp Res Jan"},{"issue":"1","key":"344_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/JCP.0b013e31820465fa","volume":"31","author":"HR Kranzler","year":"2011","unstructured":"Kranzler HR, Armeli S, Tennen H, et al. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol Feb. 2011;31(1):22\u201330. doi:https:\/\/doi.org\/10.1097\/JCP.0b013e31820465fa.","journal-title":"J Clin Psychopharmacol Feb"},{"issue":"11","key":"344_CR19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.brat.2013.08.003","volume":"51","author":"DA Ciraulo","year":"2013","unstructured":"Ciraulo DA, Barlow DH, Gulliver SB, et al. The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders. Behav Res Ther Nov. 2013;51(11):729\u201335. doi:https:\/\/doi.org\/10.1016\/j.brat.2013.08.003.","journal-title":"Behav Res Ther Nov"},{"issue":"1\u20133","key":"344_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.drugalcdep.2011.06.026","volume":"120","author":"MD Stein","year":"2012","unstructured":"Stein MD, Kurth ME, Sharkey KM, Anderson BJ, Corso RP, Millman RP. Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial. Drug Alcohol Depend Jan. 2012;120(1\u20133):65\u201373. doi:https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.06.026.","journal-title":"Drug Alcohol Depend Jan"},{"key":"344_CR21","doi-asserted-by":"publisher","unstructured":"Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA. 2000 Aug 23\u201330 2000;284(8):963 \u2013 71. doi:https:\/\/doi.org\/10.1001\/jama.284.8.963.","DOI":"10.1001\/jama.284.8.963"},{"issue":"4","key":"344_CR22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaac.2016.01.006","volume":"55","author":"KP Conway","year":"2016","unstructured":"Conway KP, Swendsen J, Husky MM, He JP, Merikangas KR. Association of Lifetime Mental Disorders and Subsequent Alcohol and Illicit Drug Use: Results From the National Comorbidity Survey-Adolescent Supplement. J Am Acad Child Adolesc Psychiatry Apr. 2016;55(4):280\u20138. doi:https:\/\/doi.org\/10.1016\/j.jaac.2016.01.006.","journal-title":"J Am Acad Child Adolesc Psychiatry Apr"},{"key":"344_CR23","doi-asserted-by":"publisher","first-page":"g1151","DOI":"10.1136\/bmj.g1151","volume":"348","author":"G Taylor","year":"2014","unstructured":"Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ (Clinical research ed) Feb 13. 2014;348:g1151. doi:https:\/\/doi.org\/10.1136\/bmj.g1151.","journal-title":"BMJ (Clinical research ed) Feb 13"},{"key":"344_CR24","doi-asserted-by":"publisher","first-page":"h1109","DOI":"10.1136\/bmj.h1109","volume":"12","author":"KH Thomas","year":"2015","unstructured":"Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell D. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ Mar. 2015;12:350:h1109. doi:https:\/\/doi.org\/10.1136\/bmj.h1109.","journal-title":"BMJ Mar"},{"issue":"3","key":"344_CR25","first-page":"203","volume":"29","author":"M Kodl","year":"2006","unstructured":"Kodl M, Fu SS, Joseph AM. Tobacco cessation treatment for alcohol-dependent smokers: when is the best time? Alcohol Res Health. 2006;29(3):203\u20137.","journal-title":"Alcohol Res Health"},{"issue":"3","key":"344_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jad.2011.08.004","volume":"139","author":"AL Baker","year":"2012","unstructured":"Baker AL, Thornton LK, Hiles S, Hides L, Lubman DI. Psychological interventions for alcohol misuse among people with co-occurring depression or anxiety disorders: a systematic review. J Affect Disord Aug. 2012;139(3):217\u201329. doi:https:\/\/doi.org\/10.1016\/j.jad.2011.08.004.","journal-title":"J Affect Disord Aug"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00344-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-022-00344-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00344-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T17:20:59Z","timestamp":1667928059000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-022-00344-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["344"],"URL":"https:\/\/doi.org\/10.1186\/s13722-022-00344-z","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"27 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Per local University of British Columbia and Providence Health Care ethics boards, case reports do not meet the formal definition for research and ethics approval was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent, manuscript feedback, and final approval was granted by the individual to present their anonymized information and reflection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"EW served as the Chief Medical Officer at Numinus Wellness, a Canadian company interested in medical application of psychedelic substances. Numinus Wellness was not involved in the conception, planning, writing or decision to submit this manuscript for publication. EW is supported by the Canadian Institutes of Health Research through the Canada Research Chairs Program. No other competing interests were declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}